Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.61 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19084133 | 0.83 | CYP2A13 (0.56) | CYP2A13ALDH1A1KDM4ECXCR4SMN1; SMN2 | |
| SCHEMBL6944902 | 0.82 | CYP2A13 (0.59) | CYP2A13ALDH1A1KDM4ECXCR4SMN1; SMN2 | |
| SCHEMBL13202837 | 0.81 | CYP2A13 (0.54) | ACHECYP2A13ALDH1A1KDM4ECXCR4 | |
| SCHEMBL19075616 | 0.81 | CYP2A13 (0.54) | CYP2A13ALDH1A1KDM4ECXCR4SMN1; SMN2 | |
| SCHEMBL12013926 | 0.81 | CXCR4 (0.69) | ACHECYP2A13ALDH1A1KDM4ECXCR4 | |
| SCHEMBL19427317 | 0.80 | ALDH1A1 (0.59) | CYP2A13HRH3ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19430625 | 0.80 | ALDH1A1 (0.59) | CYP2A13HRH3ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18360638 | 0.80 | KDM4E (0.57) | ACHECYP2A13ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28551278 | 0.78 | CYP2A13 (0.54) | CYP2A13ALDH1A1KDM4ECXCR4SMN1; SMN2 | |
| SCHEMBL4109734 | 0.78 | CYP2A13 (0.62) | CYP2A13ALDH1A1KDM4ERAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ACHE 1652/4885CYP2A13 661/4885HRH3 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.